AIMS/HYPOTHESIS: Mechanisms responsible for the decreased high-density lipoprotein (HDL) cholesterol level associated with insulin resistance in obese patients are not clearly understood. To determine the influence of insulin resistance at an early stage on HDL metabolism, we performed a stable isotope kinetic study of apolipoprotein (apo) A-I, in five obese insulin resistant women with normal fasting triglycerides and without impaired glucose tolerance, and in five age-matched control women. METHODS: Each subject received a 16 h constant infusion of L-[1-(13)C]leucine at 0.7 mg/kg/h following a primed bolus of 0.7 mg/kg. RESULTS: ApoA-I fractional catabolic rate (FCR) was significantly increased in insulin-resistant women compared to controls (0.316+/-0.056 vs 0.210+/-0.040 per day, P<0.01), indicating a significant 50% increase of apoA-I catabolism, leading to an important reduction of plasma apoA-I residence time (3.25+/-0.59 vs 4.92+/-1.11, P<0.01). ApoA-I production rate tended to be higher in insulin resistant women than in controls (364+/-77 vs 258+/-60 mg/l/day, P=0.13), but the difference was not statistically significant. ApoA-I FCR was correlated with triglycerides during the fed state (r=0.69; P=0.026) and HDL triglycerides-esterified cholesterol ratio (r=0.73; P=0.016), suggesting that alteration of apoA-I metabolism in insulin resistance may be partly related to HDL enrichment in triglycerides. CONCLUSIONS: Our kinetic study shows that patients, at an early stage of insulin resistance (without impaired glucose tolerance nor fasting hypertriglyceridaemia), already have a significant alteration of apoA-I metabolism (increased apoA-I catabolism), which is consistent with the increased risk of atherosclerosis in this population.
AIMS/HYPOTHESIS: Mechanisms responsible for the decreased high-density lipoprotein (HDL) cholesterol level associated with insulin resistance in obesepatients are not clearly understood. To determine the influence of insulin resistance at an early stage on HDL metabolism, we performed a stable isotope kinetic study of apolipoprotein (apo) A-I, in five obese insulin resistant women with normal fasting triglycerides and without impaired glucose tolerance, and in five age-matched control women. METHODS: Each subject received a 16 h constant infusion of L-[1-(13)C]leucine at 0.7 mg/kg/h following a primed bolus of 0.7 mg/kg. RESULTS:ApoA-I fractional catabolic rate (FCR) was significantly increased in insulin-resistant women compared to controls (0.316+/-0.056 vs 0.210+/-0.040 per day, P<0.01), indicating a significant 50% increase of apoA-I catabolism, leading to an important reduction of plasma apoA-I residence time (3.25+/-0.59 vs 4.92+/-1.11, P<0.01). ApoA-I production rate tended to be higher in insulin resistant women than in controls (364+/-77 vs 258+/-60 mg/l/day, P=0.13), but the difference was not statistically significant. ApoA-I FCR was correlated with triglycerides during the fed state (r=0.69; P=0.026) and HDL triglycerides-esterified cholesterol ratio (r=0.73; P=0.016), suggesting that alteration of apoA-I metabolism in insulin resistance may be partly related to HDL enrichment in triglycerides. CONCLUSIONS: Our kinetic study shows that patients, at an early stage of insulin resistance (without impaired glucose tolerance nor fasting hypertriglyceridaemia), already have a significant alteration of apoA-I metabolism (increased apoA-I catabolism), which is consistent with the increased risk of atherosclerosis in this population.
Authors: Brian G Drew; Kerry-Anne Rye; Stephen J Duffy; Philip Barter; Bronwyn A Kingwell Journal: Nat Rev Endocrinol Date: 2012-01-24 Impact factor: 43.330
Authors: Marc Philippe; Hannes Gatterer; Erika Maria Eder; Alexander Dzien; Matthias Somavilla; Andreas Melmer; Christoph Ebenbichler; Tom Müller; Martin Burtscher Journal: J Sports Sci Med Date: 2017-03-01 Impact factor: 2.988
Authors: Miriam Martínez-Ramírez; Cristóbal Flores-Castillo; L Gabriela Sánchez-Lozada; Rocío Bautista-Pérez; Elizabeth Carreón-Torres; José Manuel Fragoso; José Manuel Rodriguez-Pérez; Fernando E García-Arroyo; Victoria López-Olmos; María Luna-Luna; Gilberto Vargas-Alarcón; Martha Franco; Oscar Pérez-Méndez Journal: Lipids Date: 2017-09-22 Impact factor: 1.880
Authors: B Vergès; E Florentin; S Baillot-Rudoni; S Monier; J M Petit; D Rageot; P Gambert; L Duvillard Journal: Diabetologia Date: 2008-06-05 Impact factor: 10.122
Authors: Sangeeta R Kashyap; Abdullah Osme; Serguei Ilchenko; Makan Golizeh; Kwangwon Lee; Shuhui Wang; James Bena; Stephen F Previs; Jonathan D Smith; Takhar Kasumov Journal: J Clin Endocrinol Metab Date: 2018-02-01 Impact factor: 5.958
Authors: Bruno Vergès; Emmanuel Florentin; Sabine Baillot-Rudoni; Jean-Michel Petit; Marie Claude Brindisi; Jean-Paul Pais de Barros; Laurent Lagrost; Philippe Gambert; Laurence Duvillard Journal: J Lipid Res Date: 2009-01-22 Impact factor: 5.922